<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">26089654</PMID>
      <DateCompleted>
        <Year>2016</Year>
        <Month>02</Month>
        <Day>18</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2018</Year>
        <Month>12</Month>
        <Day>03</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">1178-1998</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>10</Volume>
            <PubDate>
              <Year>2015</Year>
            </PubDate>
          </JournalIssue>
          <Title>Clinical interventions in aging</Title>
          <ISOAbbreviation>Clin Interv Aging</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Zonisamide in the management of epilepsy in the elderly.</ArticleTitle>
        <Pagination>
          <StartPage>931</StartPage>
          <EndPage>937</EndPage>
          <MedlinePgn>931-7</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.2147/CIA.S50819</ELocationID>
        <Abstract>
          <AbstractText>Zonisamide (ZNS), a second-generation antiepileptic drug, indicated as add-on treatment of focal epilepsy, has been recently approved as monotherapy for the treatment of partial seizures in adults affected by newly diagnosed epilepsy in Europe. Evidence on the efficacy and tolerability of antiepileptic drugs in the elderly is still lacking as these patients are frequently excluded from clinical trials. Here, a comprehensive overview of available data regarding the use of ZNS in the treatment of epilepsy in elderly people is provided. In a pooled analysis conducted in patients aged ≥65 years, no new/unexpected safety findings have emerged. Few data from uncontrolled investigations suggest that ZNS may be effective and well tolerated when administered as monotherapy or adjunctive antiepileptic treatment in the elderly. However, evidence from these observational studies is less than satisfactory, and randomized controlled trials focused on these patients are still needed.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Romigi</LastName>
            <ForeName>Andrea</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Istituto Neurologico Mediterraneo, IRCCS Neuromed, Pozzilli (IS), Italy ; Neurophysiopathology Department, University of Rome Tor Vergata, Rome, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Femia</LastName>
            <ForeName>Eti A</ForeName>
            <Initials>EA</Initials>
            <AffiliationInfo>
              <Affiliation>Dipartimento di Scienze della Salute, Università degli Studi di Milano, Milano, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fattore</LastName>
            <ForeName>Cinzia</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Clinical Trial Centre &amp; Antiepileptic Drugs, C. Mondino National Neurological Institute, Pavia, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vitrani</LastName>
            <ForeName>Giuseppe</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Istituto Neurologico Mediterraneo, IRCCS Neuromed, Pozzilli (IS), Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Di Gennaro</LastName>
            <ForeName>Giancarlo</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Istituto Neurologico Mediterraneo, IRCCS Neuromed, Pozzilli (IS), Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Franco</LastName>
            <ForeName>Valentina</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>Clinical Trial Centre &amp; Antiepileptic Drugs, C. Mondino National Neurological Institute, Pavia, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2015</Year>
          <Month>06</Month>
          <Day>08</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Clin Interv Aging</MedlineTA>
        <NlmUniqueID>101273480</NlmUniqueID>
        <ISSNLinking>1176-9092</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007555">Isoxazoles</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>459384H98V</RegistryNumber>
          <NameOfSubstance UI="D000078305">Zonisamide</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004827" MajorTopicYN="N">Epilepsy</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007555" MajorTopicYN="N">Isoxazoles</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000078305" MajorTopicYN="N">Zonisamide</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">efficacy</Keyword>
        <Keyword MajorTopicYN="N">elderly</Keyword>
        <Keyword MajorTopicYN="N">epilepsy</Keyword>
        <Keyword MajorTopicYN="N">safety</Keyword>
        <Keyword MajorTopicYN="N">zonisamide</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2015</Year>
          <Month>6</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2015</Year>
          <Month>6</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2016</Year>
          <Month>2</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">26089654</ArticleId>
        <ArticleId IdType="pmc">PMC4467644</ArticleId>
        <ArticleId IdType="doi">10.2147/CIA.S50819</ArticleId>
        <ArticleId IdType="pii">cia-10-931</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Johnston A, Smith PE. Epilepsy in the elderly. Expert Rev Neurother. 2010;10:1899–1910.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21384700</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stephen LJ, Brodie MJ. Epilepsy in elderly people. Lancet. 2000;355:1441–1446.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10791538</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Faught E, Richman J, Martin R, et al.  Incidence and prevalence of epilepsy among older U.S. Medicare beneficiaries. Neurology. 2012;78:448–453.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3280050</ArticleId>
            <ArticleId IdType="pubmed">22262750</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trinka E, Giorgi L, Patten A, Segieth J. Safety and tolerability of zonisamide in elderly patients with epilepsy. Acta Neurol Scand. 2013;128:422–428.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23773051</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trinka E. Epilepsy: comorbidity in the elderly. Acta Neurol Scand Suppl. 2003;180:33–36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14510818</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brodie MJ, Elder AT, Kwan P. Epilepsy in later life. Lancet Neurol. 2009;8:1019–1030.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19800848</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saetre E, Perucca E, Isojärvi J, Gjerstad L, LAM 40089 Study Group  An international multicenter randomized double-blind controlled trial of lamotrigine and sustained-release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Epilepsia. 2007;48:1292–1302.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17561956</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rowan AJ, Ramsay RE, Collins JF, et al. VA Cooperative Study 428 Group  New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. Neurology. 2005;64:1868–1873.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15955935</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brodie MJ, Overstall PW, Giorgi L. Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Res. 1999;37:81–87.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10515178</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Werhahn KJ, Klimpe S, Balkaya S, Trinka E, Krämer G. The safety and efficacy of add-on levetiracetam in elderly patients with focal epilepsy: a one-year observational study. Seizure. 2011;20:305–311.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21257324</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kutluay E, McCague K, D’Souza J, Beydoun A. Safety and tolerability of oxcarbazepine in elderly patients with epilepsy. Epilepsy Behav. 2003;4:175–180.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12697143</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giorgi L, Gomez G, O’Neill F, Hammer AE, Risner M. The tolerability of lamotrigine in elderly patients with epilepsy. Drugs Aging. 2001;18:621–630.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11587248</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zaccara G, Specchio LM. Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature. Neuropsychiatr Dis Treat. 2009;5:249–259.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2695225</ArticleId>
            <ArticleId IdType="pubmed">19557119</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Romigi A, Izzi F, Placidi F, et al.  Effects of zonisamide as add-on therapy on sleep-wake cycle in focal epilepsy: a polysomnographic study. Epilepsy Behav. 2013;26:170–174.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23312598</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brodie MJ, Ben-Menachem E, Chouette I, Giorgi L. Zonisamide: its pharmacology, efficacy and safety in clinical trials. Acta Neurol Scand Suppl. 2012;194:19–28.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23106522</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shah J, Shellenberger K, Canafax D.  ZNS: chemistry, biotransformation, and pharmacokinetics. In: Levy R, Mattson R, Meldrum B, editors. Antiepileptic Drugs. 5th ed. Philadelphia (PA): Lippincott Williams and Wilkins; 2002. pp. 872–884.</Citation>
        </Reference>
        <Reference>
          <Citation>Eisai Pharmaceuticals Inc  . Zonegran (Prescribing Information) Tea-neck (NJ): Eisai Pharmaceuticals Inc; 2004. </Citation>
        </Reference>
        <Reference>
          <Citation>Wroe SJ.  Zonisamide. In: Simon Shorvon EP, Engel J, editors. Treatment of Epilepsy. 3rd ed. Oxford: Wiley-Blackwell; 2009. p. 1200.</Citation>
        </Reference>
        <Reference>
          <Citation>Ueda Y, Doi T, Tokumaru J, Willmore LJ. Effect of zonisamide on molecular regulation of glutamate and GABA transporter proteins during epileptogenesis in rats with hippocampal seizures. Brain Res Mol Brain Res. 2003;116:1–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12941455</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Okada M, Kaneko S, Hirano T, et al.  Effects of zonisamide on dopaminergic system. Epilepsy Res. 1995;22:193–205.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8991786</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peters DH, Sorkin EM. Zonisamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy. Drugs. 1993;45:760–787.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7686468</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Faught E, Ayala R, Montouris GG, Leppik IE, Zonisamide 922 Trial Group  Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology. 2001;57:1774–1779.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11723262</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Masuda Y, Noguchi H, Karasawa T. Evidence against a significant implication of carbonic anhydrase inhibitory activity of zonisamide in its anticonvulsive effects. Arzneimittelforschung. 1994;44:267–269.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8192690</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Italiano D, Perucca E. Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age: an update. Clin Pharmacokinet. 2013;52:627–645.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23640503</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ragueneau-Majlessi I, Levy RH, Bergen D, et al.  Carbamazepine pharmacokinetics are not affected by zonisamide: in vitro mechanistic study and in vivo clinical study in epileptic patients. Epilepsy Res. 2004;62:1–11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15519127</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ragueneau-Majlessi I, Levy RH, Brodie M, Smith D, Shah J, Grundy JS. Lack of pharmacokinetic interactions between steady-state zonisamide and valproic acid in patients with epilepsy. Clin Pharmacokinet. 2005;44:517–523.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15871637</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Levy RH, Ragueneau-Majlessi I, Garnett WR, et al.  Lack of a clinically significant effect of zonisamide on phenytoin steady-state pharmacokinetics in patients with epilepsy. J Clin Pharmacol. 2004;44:1230–1234.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15496640</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Levy RH, Ragueneau-Majlessi I, Brodie MJ, Smith DF, Shah J, Pan WJ. Lack of clinically significant pharmacokinetic interactions between zonisamide and lamotrigine at steady state in patients with epilepsy. Ther Drug Monit. 2005;27:193–198.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15795651</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sills G, Brodie M. Pharmacokinetics and drug interactions with zonisamide. Epilepsia. 2007;48:435–441.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17319920</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frampton JE, Scott LJ. Zonisamide: a review of its use in the management of partial seizures in epilepsy. CNS Drugs. 2005;19:347–367.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15813651</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wallace J, Shellenberger K, Groves L. Pharmacokinetics of zonisamide in young and elderly subjects [abstract no.6.049] Epilepsia. 1998;39:190–191.</Citation>
        </Reference>
        <Reference>
          <Citation>Eisai Limited  A study to evaluate the safety and tolerability and explore the efficacy of zonisamide as add-on therapy in elderly patients with refractory partial seizures. 2014.  [Accessed November 20, 2014].  Available from:  http://www.clinicaltrials.gov/show/show/NCT01546688. NLM identifier: NCT01546688.</Citation>
        </Reference>
        <Reference>
          <Citation>Ramsay RE. Zonisamide (ZNS, Zonegran (R)): efficacy and safety stratified by patient age, p292. abstracts from the 25th International Epilepsy Congress Lisbon, Portugal October 12–16, 2003. Epilepsia. 2003;44:1–223.</Citation>
        </Reference>
        <Reference>
          <Citation>Hasegawa H. Zonisamide adjunct therapy for elderly intractable seizure in VA outpatient clinic; American Epilepsy Society Annual Meeting; 2003.  Abstract 1.038. Available from:  www.aesnet.org/meetings_events/annual_meeting_abstracts/view/2084.</Citation>
        </Reference>
        <Reference>
          <Citation>Tosches W, Tisdell J. Epilepsy in the older patient: US experience with long-term zonisamide therapy (p535). 7th European Congress on Epileptology Helsinki, Finland, 2–6 July 2006. Epilepsia. 2006;47:117–148.</Citation>
        </Reference>
        <Reference>
          <Citation>Arif H, Buchsbaum R, Pierro J, et al.  Comparative effectiveness of 10 antiepileptic drugs in older adults with epilepsy. Arch Neurol. 2010;67:408–415.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20385905</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arif H, Mendiratta A, Hirsch L.  Management of epilepsy in the elderly. In: Shorvon S, Perucca E, Engel J Jr, editors. The Treatment of Epilepsy. Hoboken: Wiley-Blackwell; 2009. pp. 203–218.</Citation>
        </Reference>
        <Reference>
          <Citation>Bergey G. Initial treatment of epilepsy: special issues in treating the elderly. Neurology. 2004;63:S40–S48.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15557550</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>White JR, Walczak TS, Marino SE, Beniak TE, Leppik IE, Birnbaum AK. Zonisamide discontinuation due to psychiatric and cognitive adverse events: a case-control study. Neurology. 2010;75:513–518.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2918476</ArticleId>
            <ArticleId IdType="pubmed">20697103</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Romigi A, Cervellino A, Marciani MG, et al.  Cognitive and psychiatric effects of topiramate monotherapy in migraine treatment: an open study. Eur J Neurol. 2008;15:190–195.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18217888</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cavanna AE, Seri S. Psychiatric adverse effects of zonisamide in patients with epilepsy and mental disorder comorbidities. Epilepsy Behav. 2013;29:281–284.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24070880</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eskandari D, Zou D, Karimi M, Stenlöf K, Grote L, Hedner J. Zonisamide reduces obstructive sleep apnoea: a randomised placebo-controlled study. Eur Respir J. 2014;44:140–149.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24627538</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gadde KM, Kopping MF, Wagner HR, 2nd, Yonish GM, Allison DB, Bray GA. Zonisamide for weight reduction in obese adults: a 1-year randomized controlled trial. Arch Intern Med. 2012;172:1557–1564.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3753218</ArticleId>
            <ArticleId IdType="pubmed">23147455</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mohammadianinejad SE, Abbasi V, Sajedi SA, et al.  Zonisamide versus topiramate in migraine prophylaxis: a double-blind randomized clinical trial. Clin Neuropharmacol. 2011;34:174–177.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21738025</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karceski S, Morrell MJ, Carpenter D. Treatment of epilepsy in adults: expert opinion, 2005. Epilepsy Behav. 2005;7(Suppl 1):S1–S64. quiz S65–S67.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16102515</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
